Form 4: Incyte EVP Receives RSU Grant, Sells Shares for Tax

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, received a grant of 7,426 restricted stock units and subsequently disposed of 429 shares to cover tax withholding obligations.

Summary

• Michael James Morrissey, EVP, Head of Tech. Operations at Incyte Corp (INCY), reported changes in his beneficial ownership of common stock.
• On January 16, 2026, Morrissey was awarded 7,426 restricted stock units (RSUs) at a price of $0, which will vest 25% annually over four years.
• Following this RSU grant, his direct beneficial ownership increased to 34,679 shares.
• On January 20, 2026, Morrissey disposed of 429 shares of common stock at a price of $102.62 per share.
• This disposition was an automatic withholding by Incyte to satisfy tax obligations due at the settlement of previously reported restricted stock units.
• After the tax-related disposition, Morrissey's direct beneficial ownership stands at 34,250 shares.
• The reported beneficial ownership includes an aggregate of 25,198 shares issuable pursuant to previously reported unvested restricted stock units and earned performance stock units.

Sentiment

Score: 6

Explanation: The filing reflects routine executive compensation and tax-related stock transactions, which are generally neutral to slightly positive as they indicate ongoing executive retention and standard compensation practices.

Positives

• The grant of 7,426 restricted stock units (RSUs) at a $0 price represents a significant component of executive compensation, aligning management's interests with long-term shareholder value.
• The RSU vesting schedule (25% annually over four years) promotes executive retention and sustained performance.

Negatives

• The disposition of 429 shares, while for tax purposes, reduces the executive's direct beneficial ownership of common stock.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on executive stock transactions.

Industry Context

The grant of restricted stock units and subsequent disposition of shares for tax withholding are standard practices in executive compensation across the biotechnology and pharmaceutical industries. This reflects a common approach to incentivize and retain key management personnel.

Comparison to Industry Standards

• The RSU grant as a form of equity compensation is a widely adopted practice among publicly traded companies, particularly in high-growth sectors like biotech, to align executive incentives with shareholder returns.
• The 'sell to cover' mechanism for tax withholding is a standard and efficient method for executives to meet tax obligations arising from the vesting of equity awards, consistent with practices observed at comparable companies in the S&P 500.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and stock ownership, which is a routine aspect of corporate governance.
• Employees: Reflects standard executive compensation practices, which may influence broader compensation strategies within the company.

Next Steps

• The granted restricted stock units will vest 25% annually over four years, leading to future share issuances upon vesting.

Key Dates

Recommendation

This Form 4 details routine executive compensation (an RSU grant) and a standard tax-related share disposition. Such transactions are generally not indicative of a change in the company's fundamental outlook or a reason to alter an investment thesis based solely on this filing. Investors should continue to evaluate Incyte based on its financial performance, pipeline, and market position.

Keywords

Incyte, INCY, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Executive Compensation, Stock Ownership, Tax Withholding